SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on October 24, 2022. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes and Events
- Strategic Partnership: On October 24, 2022, the Company signed a master research agreement with Cleveland Clinic.
- Objective: The agreement aims to explore expanded applications for the Company's digital signal processing technology.
- Disclosure: A press release detailing this agreement was issued on the same date and is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the general context of the new research agreement. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific terms of the Cleveland Clinic agreement.
- Verify the potential commercial impact of the digital signal processing technology expansion.
- Check subsequent filings for any financial milestones or revenue recognition related to this research agreement.